These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27486205)

  • 61. [Clinical course of the ventilatory function in COPD: analytical study of 160 cases].
    Battikh MH; Ben Sayah MM; Joobeur S; Naouar R; Maatallah A; Rouatbi N; Ben Salem K; El Kamel A
    Tunis Med; 2004 Aug; 82(8):735-41. PubMed ID: 15532768
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Plasma pro-surfactant protein B and lung function decline in smokers.
    Leung JM; Mayo J; Tan W; Tammemagi CM; Liu G; Peacock S; Shepherd FA; Goffin J; Goss G; Nicholas G; Tremblay A; Johnston M; Martel S; Laberge F; Bhatia R; Roberts H; Burrowes P; Manos D; Stewart L; Seely JM; Gingras M; Pasian S; Tsao MS; Lam S; Sin DD;
    Eur Respir J; 2015 Apr; 45(4):1037-45. PubMed ID: 25614175
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systematic review of the evidence relating FEV1 decline to giving up smoking.
    Lee PN; Fry JS
    BMC Med; 2010 Dec; 8():84. PubMed ID: 21156048
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Risk Factors of Rapid FEV1 Decline in a Real-World Chronic Obstructive Pulmonary Disease Cohort.
    Lee HW; Lee JK; Lee MG; Shin KC; Ra SW; Kim TH; Hwang YI; Jung KS; Yoo KH; Kim DK
    Respiration; 2022; 101(12):1078-1087. PubMed ID: 36349793
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.
    Willemse BW; Postma DS; Timens W; ten Hacken NH
    Eur Respir J; 2004 Mar; 23(3):464-76. PubMed ID: 15065840
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biomarkers of collagen turnover are related to annual change in FEV
    Leeming DJ; Byrjalsen I; Sand JMB; Bihlet AR; Lange P; ; Thal-Singer R; Miller BE; Karsdal MA; Vestbo J
    BMC Pulm Med; 2017 Dec; 17(1):164. PubMed ID: 29202744
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes.
    Masuko H; Sakamoto T; Kaneko Y; Iijima H; Naito T; Noguchi E; Hirota T; Tamari M; Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2011; 6():181-9. PubMed ID: 21468164
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of weight gain on pulmonary function after smoking cessation in the Lung Health Study.
    Wise RA; Enright PL; Connett JE; Anthonisen NR; Kanner RE; Lindgren P; O'Hara P; Owens GR; Rand CS; Tashkin DP
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):866-72. PubMed ID: 9517604
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
    Anthonisen NR; Connett JE; Kiley JP; Altose MD; Bailey WC; Buist AS; Conway WA; Enright PL; Kanner RE; O'Hara P
    JAMA; 1994 Nov; 272(19):1497-505. PubMed ID: 7966841
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pulmonary Arterial Pruning and Longitudinal Change in Percent Emphysema and Lung Function: The Genetic Epidemiology of COPD Study.
    Pistenmaa CL; Nardelli P; Ash SY; Come CE; Diaz AA; Rahaghi FN; Barr RG; Young KA; Kinney GL; Simmons JP; Wade RC; Wells JM; Hokanson JE; Washko GR; San José Estépar R;
    Chest; 2021 Aug; 160(2):470-480. PubMed ID: 33607083
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Peak expiratory flow rate as a surrogate for forced expiratory volume in 1 second in COPD severity classification in Thailand.
    Pothirat C; Chaiwong W; Phetsuk N; Liwsrisakun C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1213-8. PubMed ID: 26150713
    [TBL] [Abstract][Full Text] [Related]  

  • 72. External validation of lung function predictions in real-world cohorts of COPD.
    Zafari Z; Lee TY; Sadatsafavi M
    Respir Med; 2022 Jul; 198():106859. PubMed ID: 35524999
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Outcomes for symptomatic non-obstructed individuals and individuals with mild (GOLD stage 1) COPD in a population based cohort.
    Perez-Padilla R; Wehrmeister FC; de Oca MM; Lopez MV; Jardim JR; Muiño A; Valdivia G; Menezes AMB
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3549-3561. PubMed ID: 30464437
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy.
    MacDonald DM; Melzer AC; Collins G; Avihingsanon A; Crothers K; Ingraham NE; Mugerwa H; Ristola M; Shuter J; Kunisaki KM;
    J Acquir Immune Defic Syndr; 2018 Nov; 79(3):e85-e92. PubMed ID: 29985804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use.
    Petersen H; Sood A; Meek PM; Shen X; Cheng Y; Belinsky SA; Owen CA; Washko G; Pinto-Plata V; Kelly E; Celli B; Tesfaigzi Y
    Chest; 2014 Apr; 145(4):695-703. PubMed ID: 24008986
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population.
    Goffin JR; Pond GR; Puksa S; Tremblay A; Johnston M; Goss G; Nicholas G; Martel S; Bhatia R; Liu G; Schmidt H; Atkar-Khattra S; McWilliams A; Tsao MS; Tammemagi MC; Lam S
    BMC Pulm Med; 2020 Nov; 20(1):300. PubMed ID: 33198781
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.
    Calverley PMA; Anderson JA; Brook RD; Crim C; Gallot N; Kilbride S; Martinez FJ; Yates J; Newby DE; Vestbo J; Wise R; Celli BR;
    Am J Respir Crit Care Med; 2018 Jan; 197(1):47-55. PubMed ID: 28737971
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.
    Snoeck-Stroband JB; Lapperre TS; Sterk PJ; Hiemstra PS; Thiadens HA; Boezen HM; Ten Hacken NH; Kerstjens HA; Postma DS; Timens W; Sont JK;
    PLoS One; 2015; 10(12):e0143793. PubMed ID: 26659582
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Smoking cessation affects the natural history of COPD.
    Bai JW; Chen XX; Liu S; Yu L; Xu JF
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3323-3328. PubMed ID: 29180862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.